CN115252746A - Traditional Chinese medicine for treating phlebitis, traditional Chinese medicine dressing prepared from traditional Chinese medicine and adhesive plaster - Google Patents
Traditional Chinese medicine for treating phlebitis, traditional Chinese medicine dressing prepared from traditional Chinese medicine and adhesive plaster Download PDFInfo
- Publication number
- CN115252746A CN115252746A CN202211048189.2A CN202211048189A CN115252746A CN 115252746 A CN115252746 A CN 115252746A CN 202211048189 A CN202211048189 A CN 202211048189A CN 115252746 A CN115252746 A CN 115252746A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- dressing
- plaster
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 120
- 208000001297 phlebitis Diseases 0.000 title claims abstract description 40
- 239000011505 plaster Substances 0.000 title claims abstract description 38
- 239000000853 adhesive Substances 0.000 title description 5
- 230000001070 adhesive effect Effects 0.000 title description 5
- 230000000694 effects Effects 0.000 claims abstract description 25
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 15
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 15
- 235000013976 turmeric Nutrition 0.000 claims abstract description 15
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 10
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims abstract description 10
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 9
- 241001673966 Magnolia officinalis Species 0.000 claims abstract description 9
- 241001522129 Pinellia Species 0.000 claims abstract description 9
- 241000218989 Trichosanthes Species 0.000 claims abstract description 4
- 244000299790 Rheum rhabarbarum Species 0.000 claims abstract 3
- 241000972672 Phellodendron Species 0.000 claims abstract 2
- 239000010410 layer Substances 0.000 claims description 16
- 244000163122 Curcuma domestica Species 0.000 claims description 15
- 235000012907 honey Nutrition 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- 239000008227 sterile water for injection Substances 0.000 claims description 15
- 239000011241 protective layer Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 10
- 241000675108 Citrus tangerina Species 0.000 claims description 8
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 8
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 8
- 229940010454 licorice Drugs 0.000 claims description 8
- 241000209524 Araceae Species 0.000 claims description 7
- 239000012790 adhesive layer Substances 0.000 claims description 7
- 241000132012 Atractylodes Species 0.000 claims description 6
- 240000004670 Glycyrrhiza echinata Species 0.000 claims 2
- 235000014375 Curcuma Nutrition 0.000 claims 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 230000000474 nursing effect Effects 0.000 abstract description 7
- 241000489492 Arisaema Species 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 235000003398 Curcuma aromatica Nutrition 0.000 abstract 1
- 244000008991 Curcuma longa Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 210000000941 bile Anatomy 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 20
- 238000000034 method Methods 0.000 description 17
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 11
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- 235000019341 magnesium sulphate Nutrition 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 241000219061 Rheum Species 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 241000202807 Glycyrrhiza Species 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000000416 hydrocolloid Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000000860 Compassion Fatigue Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 206010034897 Phlebitis deep Diseases 0.000 description 1
- 206010065599 Puncture site pain Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 240000006023 Trichosanthes kirilowii Species 0.000 description 1
- 108010021119 Trichosanthin Proteins 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- -1 compound amino acids Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- FWZTTZUKDVJDCM-CEJAUHOTSA-M disodium;(2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;iron(3+);oxygen(2-);hydroxide;trihydrate Chemical compound O.O.O.[OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FWZTTZUKDVJDCM-CEJAUHOTSA-M 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940032961 iron sucrose Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8884—Arisaema, e.g. Jack in the pulpit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
技术领域technical field
本发明涉及静脉炎治疗领域,具体地说,是涉及一种用于治疗静脉炎的中药及其制成的中药敷料和粘贴式膏药。The invention relates to the field of phlebitis treatment, in particular to a traditional Chinese medicine for treating phlebitis and a traditional Chinese medicine dressing and sticking plaster made therefrom.
背景技术Background technique
静脉炎在临床上属于常见病和多发病,是指静脉血管的急性无菌性炎症。根据病变部位不同,其可分为浅静脉炎和深静脉炎。少数病人可有发热、白细胞总数增高等,患者常常陈诉疼痛肿胀。引起静脉血栓形成的病因很多,如创伤、手术、妊娠、分娩、心脏病等,较常见的是外科手术后引发本病。Phlebitis is a clinically common and frequently-occurring disease, which refers to acute aseptic inflammation of venous blood vessels. Depending on the location of the lesion, it can be divided into superficial phlebitis and deep phlebitis. A small number of patients may have fever, increased white blood cell count, etc., and patients often report pain and swelling. There are many causes of venous thrombosis, such as trauma, surgery, pregnancy, childbirth, heart disease, etc., and the most common cause of this disease is after surgery.
目前治疗静脉炎的方法主要有以下几种:The current methods of treating phlebitis mainly include the following:
(1)硫酸镁湿热敷:促进局部静脉血管通透性改变,促进局部组织肿胀消除,改善微循环,促进静脉回流,延缓疾病进一步发展。该法疗效较差,而且需要在医师的指导下使用,需严格控制硫酸镁的浓度以及热敷的温度;且使用时需要经常更换纱布,易弄湿床单,给患者带来极大的不便。(1) Magnesium sulfate hot compress: promote the change of local venous vascular permeability, promote the elimination of local tissue swelling, improve microcirculation, promote venous return, and delay the further development of the disease. The curative effect of this method is relatively poor, and it needs to be used under the guidance of a physician. The concentration of magnesium sulfate and the temperature of hot compress need to be strictly controlled; and the gauze needs to be changed frequently during use, which is easy to wet the bed sheet, which brings great inconvenience to the patient.
(2)喜疗妥涂擦:喜疗妥又称多磺酸粘多糖乳膏,可以起到控制炎症,改善水肿,软化疤痕的作用。使用此法时药物裸露在患处,容易被衣物擦除,导致药物在患处的持续时间缩短,进而降低疗效;而且,该药物属进口药物,很多基层医院没有此药物,且部分地区未纳入医保,无法实现大规模推广使用。(2) Hirudoid rubbing: Hirudoid, also known as polysulfonic acid mucopolysaccharide cream, can control inflammation, improve edema, and soften scars. When using this method, the drug is exposed on the affected area and is easily wiped off by clothes, which shortens the duration of the drug on the affected area, thereby reducing the curative effect; moreover, the drug is an imported drug, which is not available in many primary hospitals, and some areas are not covered by medical insurance. Unable to achieve large-scale promotion and use.
(3)贴水胶体:水胶体敷料是一种特殊高分子材料,价格较贵,且普通患者不易获得。(3) Hydrocolloid dressing: Hydrocolloid dressing is a special polymer material, which is expensive and not easy for ordinary patients to obtain.
发明内容Contents of the invention
本发明的目的在于克服现有技术的不足,提供一种用于治理静脉炎的中药,既能有效治疗静脉炎,确保疗效,又能降低使用门槛,护士、病人、家属均可使用,在提供操作便利性的同时,价格便宜,为广泛推广奠定基础。The purpose of the present invention is to overcome the deficiencies of the prior art and provide a traditional Chinese medicine for treating phlebitis, which can effectively treat phlebitis, ensure the curative effect, and reduce the threshold for use. It can be used by nurses, patients, and family members. The operation is convenient and the price is cheap, which lays the foundation for widespread promotion.
为实现上述目的,本发明采用的技术方案如下:To achieve the above object, the technical scheme adopted in the present invention is as follows:
一种用于治疗静脉炎的中药,包括以下重量配比的组分:姜黄150-180份、大黄150-180份、黄柏150-170份、白芷150-170份、天花粉300-350份、郁金150-170份、石菖蒲150-170份、半夏50-70份、苍术50-70份、厚朴50-70份、陈皮50-70份、生天南星50-70份、甘草50-70份。A traditional Chinese medicine for treating phlebitis, comprising the following components by weight: 150-180 parts of turmeric, 150-180 parts of rhubarb, 150-170 parts of Cortex Phellodendri, 150-170 parts of Angelica dahurica, 300-350 parts of trichosanthes, 150-170 parts of gold, 150-170 parts of Shichangpu, 50-70 parts of pinellia, 50-70 parts of herb, 50-70 parts of Magnolia officinalis, 50-70 parts of dried tangerine peel, 50-70 parts of raw araceae, 50-70 parts of licorice share.
进一步地,上述各组分为:姜黄160份,大黄160份,黄柏160份,白芷160份,天花粉320份,郁金160份,石菖蒲160份,半夏64份、苍术64份、厚朴64份、陈皮64份、生天南星64份,甘草64份。Further, the above-mentioned components are: 160 parts of turmeric, 160 parts of rhubarb, 160 parts of Cortex Phellodendri, 160 parts of Angelica dahurica, 320 parts of Tianhua Fen, 160 parts of turmeric, 160 parts of Shichangpu, 64 parts of pinellia, 64 parts of atractylodes, Magnolia officinalis 64 parts, 64 parts of tangerine peel, 64 parts of raw Araceae, 64 parts of licorice.
为了方便用药,本发明还提供了由上述中药制成的中药敷料,由权利要求1或2所述的中药材粉碎成细粉,加入蜂蜜和灭菌注射用水,混合均匀成干糊状制得,且中药细粉、蜂蜜、灭菌注射用水的重量比为3:1:4。In order to facilitate medication, the present invention also provides a traditional Chinese medicine dressing made of the above-mentioned traditional Chinese medicine, which is prepared by pulverizing the Chinese medicinal material described in claim 1 or 2 into fine powder, adding honey and sterilized water for injection, and mixing evenly to form a dry paste , and the weight ratio of fine powder of traditional Chinese medicine, honey, and sterile water for injection is 3:1:4.
更进一步地,上述中药敷料先均匀地涂覆于患处表面,且超过患处边缘1-2cm;所述中药敷料涂于患处的厚度为硬币厚度;然后用创可贴粘贴于所述中药敷料表面,固定且遮盖该中药敷料。Further, the above-mentioned traditional Chinese medicine dressing is evenly coated on the surface of the affected area, and exceeds the edge of the affected area by 1-2cm; the thickness of the traditional Chinese medicine dressing applied to the affected area is the thickness of a coin; Cover the herbal dressing.
再进一步地,所述中药敷料每天使用两次,每次敷药时间4-6个小时,上一次敷药完毕后,至少间隔1个小时再进行下一次敷药。Still further, the traditional Chinese medicine dressing is used twice a day, and the dressing time is 4-6 hours each time. After the last dressing is completed, the next dressing is performed at an interval of at least 1 hour.
为了使每次敷药的效果达到最佳,每次换药前,先使用20-30℃的温水清洗患处,将上一次涂覆的中药敷料完全清洗掉以后,再涂覆新的中药敷料。In order to achieve the best effect of each dressing, wash the affected area with warm water at 20-30°C before each dressing change, and then apply a new Chinese herbal dressing after completely washing off the last applied Chinese herbal dressing.
为了保证疗效,上述中药敷料至少需连续敷药3-5天即可见效,炎症减轻或局部症状缓解,肉眼可见症状明显改善。中途不可中断。In order to ensure the curative effect, the above-mentioned traditional Chinese medicine dressing needs to be applied continuously for at least 3-5 days to be effective, the inflammation is relieved or the local symptoms are relieved, and the symptoms are obviously improved by the naked eye. Cannot be interrupted in the middle.
为了便于将本发明中的中药敷料形成产业化,便于推广销售和使用,本发明还提供了一种由上述中药敷料制成的粘贴式膏药,包括膏药基体层、膏药保护层和权利要求3所述的中药敷料,所述中药敷料涂覆于所述膏药基体层的中部,在该膏药基体层的两端分别设置有粘贴层,所述膏药保护层将所述中药敷料和粘贴层包覆在膏药基体层与膏药保护层之间,且膏药保护层可独立撕开。In order to facilitate the industrialization of the traditional Chinese medicine dressing in the present invention, and to promote sales and use, the present invention also provides an adhesive plaster made from the above-mentioned traditional Chinese medicine dressing, which includes a plaster base layer, a plaster protective layer and claim 3. The above-mentioned traditional Chinese medicine dressing, the traditional Chinese medicine dressing is coated on the middle part of the plaster base layer, and the two ends of the plaster base layer are respectively provided with an adhesive layer, and the plaster protective layer covers the traditional Chinese medicine dressing and the adhesive layer between the plaster base layer and the plaster protective layer, and the plaster protective layer can be torn apart independently.
本发明中的粘贴式膏药,类似于现有技术中的创可贴,但将创可贴中的药物成分替换成本发明中的中药敷料,使用时直接将膏药保护层撕掉,将中药敷料对准患处位置,利用膏药基体层两端的粘贴层将中药敷料粘贴在患处即可。此类技术目前已经十分成熟,在此不做详细描述。The adhesive plaster in the present invention is similar to the Band-Aid in the prior art, but the medicinal ingredients in the Band-Aid are replaced with the traditional Chinese medicine dressing in the present invention, and the protective layer of the plaster is directly torn off when in use, and the traditional Chinese medicine dressing is aligned with the affected area. The traditional Chinese medicine dressing can be pasted on the affected part by using the pasting layers at both ends of the plaster base layer. This type of technology is already very mature and will not be described in detail here.
本方中,天花粉苦寒微酸,能消肿止痛,清热解毒,收束疮根,使疮内消,故为君药。臣药以姜黄、大黄,一热一寒,化瘀活血,行气通经,消肿止痛;郁金活血止痛,行气解郁,清心凉血;黄柏清湿,消肿毒,收湿束疮;白芷祛风除湿,收湿敛疮,消肿止痛;且白芷善散气分之结,大黄善破血分之瘀,二药配伍,使气行血散。佐药以陈皮、苍术、厚朴芳香行散,以行气活血;半夏燥湿化痰,消肿散结,石菖蒲化湿和胃,祛痰;天南星除痰散血而消散痈肿,助天花粉之清凉解毒,从而使肿毒内消。使药甘草调和诸药,缓急止痛。In this prescription, Trichosanthes trichosanthes is bitter, cold and slightly sour, can reduce swelling and relieve pain, clear away heat and detoxify, bind the root of sore, and make the sore disappear internally, so it is the king medicine. The ministerial medicine is turmeric and rhubarb, one heat and one cold, dissipating blood stasis and promoting blood circulation, promoting qi and dredging the meridian, reducing swelling and relieving pain; turmeric promoting blood circulation and relieving pain, promoting qi and relieving depression, clearing heart and cooling blood; Sores; Angelica dahurica dispels wind and dampness, reduces dampness and suppresses sores, reduces swelling and relieves pain; and Angelica dahurica is good at dispelling the knot of qi, and rhubarb is good at breaking the stasis of blood. The adjuvant medicines are tangerine peel, atractylodes atractylodes, and Magnolia officinalis fragrance, which are used to promote qi and blood circulation; Pinellia to dry dampness and reduce phlegm, reduce swelling and dissipate stagnation; Help the cooling and detoxification of trichosanthum pollen, so that the swelling and poison can be eliminated internally. Make medicine licorice to reconcile various medicines, relieve spasm and relieve pain.
全方配伍,主以苦寒清泄,兼以辛温行散,共奏清热解毒、消肿止痛之功,可用于症见红肿热痛的静脉炎、疮疡等。The combination of all prescriptions mainly uses bitter and cold to clear away diarrhea, and also uses pungent and warm to dissipate. They play the role of clearing away heat and detoxification, reducing swelling and relieving pain.
与现有技术相比,本发明具有以下有益效果:Compared with the prior art, the present invention has the following beneficial effects:
(1)本发明中君臣使佐选材合理,用量得当,能够起到相互支撑、相互促进的作用,使各种药材的药性充分发挥,治疗静脉炎时,效果显著,治愈率高,安全无毒副作用。(1) In the present invention, the selection of materials by the monarch and ministers is reasonable, and the dosage is appropriate, which can play a role of mutual support and mutual promotion, so that the medicinal properties of various medicinal materials can be fully exerted. When treating phlebitis, the effect is remarkable, the cure rate is high, and it is safe and non-toxic side effect.
(2)本发明使用的所有药材均为常规药材,价格便宜,易于采购,使用无技术门槛,直接涂覆在患处即可,操作方便,非常适合批量生产,大规模推广应用。(2) All the medicinal materials used in the present invention are conventional medicinal materials, which are cheap, easy to purchase, and have no technical threshold for use. They can be directly applied to the affected area, easy to operate, and very suitable for mass production and large-scale application.
(3)本发明中,每次换药前,使用温水清洗患处,一方面洗掉患处残留的药渣,避免上一次涂抹的药物形成药垢,阻挡新药物作用于患处发挥疗效;同时,温水能够使患处皮肤松弛,扩大毛孔,提高吸收效率,便于新药物快速渗透皮肤,产生疗效。(3) In the present invention, before changing the dressing each time, use warm water to clean the affected part. On the one hand, wash off the residual medicine residue in the affected part, avoid the drug scale formed by the medicine applied last time, and prevent new medicine from acting on the affected part to exert curative effect; meanwhile, warm water It can relax the skin of the affected area, expand the pores, improve the absorption efficiency, and facilitate the rapid penetration of new drugs into the skin to produce curative effect.
(4)本发明提供的中药敷料,每天只需更换一次用药,其他时间无需频繁更换纱布,不会弄湿床单,易于护理,十分方便。而且,两次用药保证至少间隔1个小时以上,给患处皮肤预留了足够的休息时间,使皮肤在治疗期间的过程中,拥有了适当的时间与空气自然接触,保证了患处皮肤的活性,能够有效加快炎症消退,促进患处皮肤的康复。(4) The traditional Chinese medicine dressing provided by the present invention only needs to replace the medicine once a day, and does not need to frequently replace the gauze at other times, and the bed sheets will not be wet, so it is easy to care and is very convenient. Moreover, the interval between the two medications is guaranteed to be at least 1 hour, so that enough rest time is reserved for the skin of the affected area, so that the skin has an appropriate time to naturally contact with the air during the treatment period, ensuring the activity of the skin of the affected area. It can effectively speed up the disappearance of inflammation and promote the recovery of the affected skin.
(5)本发明采用蜂蜜和灭菌注射用水来调和药材细粉,选择比例恰当,不仅能够长效保湿,确保粘稠度和湿度,而且有效隔绝细菌,避免了普通水中存在细菌影响疗效的问题。(5) The present invention uses honey and sterilized water for injection to reconcile the fine powder of medicinal materials, and the proportion is appropriate, which can not only keep moisture for a long time, ensure viscosity and humidity, but also effectively isolate bacteria, avoiding the problem that bacteria in ordinary water affect the curative effect .
(6)本发明只需要连续涂覆3-5天即可见效,疗程短,成本低,非常适合普通老百姓使用。(6) The present invention only needs to be applied continuously for 3-5 days to be effective, the course of treatment is short, and the cost is low, which is very suitable for ordinary people to use.
(7)本发明制成的粘贴式膏药,类似于创可贴,不仅使用方便,易于保存携带,而且易于推广应用。(7) The adhesive plaster made by the present invention is similar to a Band-Aid, not only easy to use, easy to store and carry, but also easy to popularize and apply.
具体实施方式Detailed ways
下面结合实施例对本发明作进一步说明,本发明的方式包括但不仅限于以下实施例。The present invention will be further described below in conjunction with the examples, and the mode of the present invention includes but not limited to the following examples.
实施例1Example 1
本实施例提供的中药,包括以下重量配比的组分:姜黄150份、大黄150份、黄柏150份、白芷150份、天花粉350份、郁金150份、石菖蒲170份、半夏70份、苍术70份、厚朴70份、陈皮70份、生天南星70份、甘草70份。The traditional Chinese medicine provided in this embodiment includes the following components by weight: 150 parts of turmeric, 150 parts of rhubarb, 150 parts of Cortex Phellodendri, 150 parts of Angelica dahurica, 350 parts of Tianhuafen, 150 parts of turmeric, 170 parts of Shichangpu, and 70 parts of pinellia , 70 parts of Atractylodes atractylodes, 70 parts of Magnolia officinalis, 70 parts of tangerine peel, 70 parts of raw Araceae, and 70 parts of licorice.
本实施例将上述中药材粉碎成细粉,加入蜂蜜和灭菌注射用水,将其混合均匀,调和成干糊状,制成中药敷料,使用时将其敷在皮肤患处。为了保证中药敷料的干湿程度最佳,本实施例中,中药细粉、蜂蜜、灭菌注射用水的重量比选择3:1:4,即中药细粉共1690g,蜂蜜563g,灭菌注射用水2253g。In this embodiment, the above-mentioned Chinese medicinal materials are crushed into fine powder, honey and sterilized water for injection are added, mixed evenly, and reconciled into a dry paste to make a traditional Chinese medicine dressing, which is applied to the affected part of the skin during use. In order to ensure the best dryness and wetness of Chinese medicine dressings, in this embodiment, the weight ratio of Chinese medicine fine powder, honey, and sterilized water for injection is selected as 3:1:4, that is, Chinese medicine fine powder is 1690g, honey 563g, and sterilized water for injection 2253g.
实施例2Example 2
本实施例提供的中药,包括以下重量配比的组分:姜黄180份、大黄180份、黄柏170份、白芷170份、天花粉300份、郁金170份、石菖蒲150份、半夏50份、苍术50份、厚朴50份、陈皮50份、生天南星50份、甘草50份。The traditional Chinese medicine provided in this embodiment includes the following components by weight: 180 parts of turmeric, 180 parts of rhubarb, 170 parts of Cortex Phellodendri, 170 parts of Angelica dahurica, 300 parts of Tianhua Fen, 170 parts of turmeric, 150 parts of Shichangpu, 50 parts of pinellia , 50 parts of Atractylodes atractylodes, 50 parts of Magnolia officinalis, 50 parts of tangerine peel, 50 parts of raw Araceae, and 50 parts of licorice.
本实施例将上述中药材粉碎成细粉,加入蜂蜜和灭菌注射用水,将其混合均匀,调和成干糊状,制成中药敷料,使用时将其敷在皮肤患处。为了保证中药敷料的干湿程度最佳,本实施例中,中药细粉、蜂蜜、灭菌注射用水的重量比选择3:1:4,即中药细粉共1620g,蜂蜜540g,灭菌注射用水2160g。In this embodiment, the above-mentioned Chinese medicinal materials are crushed into fine powder, honey and sterilized water for injection are added, mixed evenly, and reconciled into a dry paste to make a traditional Chinese medicine dressing, which is applied to the affected part of the skin during use. In order to ensure the best dryness and wetness of the Chinese medicine dressing, in the present embodiment, the weight ratio of Chinese medicine fine powder, honey, and sterile water for injection is selected as 3:1:4, that is, a total of 1620g of Chinese medicine fine powder, 540g of honey, and sterile water for injection 2160g.
实施例3Example 3
本实施例提供的中药,包括以下重量配比的组分:姜黄160份、大黄160份、黄柏160份、白芷160份、天花粉320份、郁金160份、石菖蒲160份、半夏64份、苍术64份、厚朴64份、陈皮64份、生天南星64份、甘草64份。The traditional Chinese medicine provided in this embodiment includes the following components by weight: 160 parts of turmeric, 160 parts of rhubarb, 160 parts of Cortex Phellodendri, 160 parts of Angelica dahurica, 320 parts of Tianhua Fen, 160 parts of turmeric, 160 parts of Shichangpu, and 64 parts of pinellia , 64 parts of Atractylodes atractylodes, 64 parts of Magnolia officinalis, 64 parts of tangerine peel, 64 parts of raw Araceae, 64 parts of licorice.
本实施例将上述中药材粉碎成细粉,加入蜂蜜和灭菌注射用水,将其混合均匀,调和成干糊状,制成中药敷料,使用时将其敷在皮肤患处。为了保证中药敷料的干湿程度最佳,本实施例中,中药细粉、蜂蜜、灭菌注射用水的重量比选择3:1:4,即中药细粉共1664g,蜂蜜555g,灭菌注射用水2219g。In this embodiment, the above-mentioned Chinese medicinal materials are crushed into fine powder, honey and sterilized water for injection are added, mixed evenly, and reconciled into a dry paste to make a traditional Chinese medicine dressing, which is applied to the affected part of the skin during use. In order to ensure the best dryness and wetness of Chinese medicine dressings, in this embodiment, the weight ratio of Chinese medicine fine powder, honey, and sterilized water for injection is selected to be 3:1:4, that is, a total of 1664g of Chinese medicine fine powder, 555g of honey, and sterilized water for injection 2219g.
在本技术中,蜂蜜能够起到赋形剂和长效保湿的作用,使整个中药敷料长期保持稳定的粘稠度和湿度,一次调和,可长时间密封存放,为批量制药、随时使用奠定了可靠的基础。灭菌注射用水杜绝了水中细菌的存在,大大降低了敷料中携带细菌,对患者造成二次创伤或感染的几率。因此,按照本方法制成的中药敷料,可在不降低药效的同时,长时间密封保存。In this technology, honey can act as an excipient and long-term moisturizing effect, so that the whole traditional Chinese medicine dressing can maintain a stable viscosity and humidity for a long time, once reconciled, it can be sealed and stored for a long time, laying the foundation for batch pharmacy and use at any time reliable foundation. The sterilized water for injection eliminates the existence of bacteria in the water, greatly reducing the probability of carrying bacteria in the dressing and causing secondary trauma or infection to the patient. Therefore, the traditional Chinese medicine dressing made according to the method can be sealed and stored for a long time without reducing the efficacy of the medicine.
使用时,先用一次性压舌板将中药敷料均匀地涂于患处表面,超过患处边缘1-2cm,确保中药敷料将患处完全覆盖;中药敷料涂抹均匀,厚度约为硬币厚度,使患处表面受药均匀,所有位置药力相当;然后,用创可贴粘贴在中药敷料表面,将中药敷料遮盖并固定,避免在用药过程中药物受外物影响而移动或脱落,导致药物失效或降低药力。用药频率保持每天使用两次,每次敷药时间4-6个小时,上一次敷药完毕后,至少间隔1个小时再进行下一次敷药。When using, first use a disposable tongue depressor to apply the Chinese medicine dressing evenly on the surface of the affected area, 1-2cm beyond the edge of the affected area to ensure that the Chinese medicine dressing completely covers the affected area; apply the Chinese medicine dressing evenly, and the thickness is about the thickness of a coin. The medicine is uniform, and the medicine strength is equal in all positions; then, use a band-aid to paste on the surface of the traditional Chinese medicine dressing, cover and fix the traditional Chinese medicine dressing, so as to prevent the medicine from moving or falling off due to the influence of foreign objects during the medication process, which will cause the medicine to fail or reduce the medicine efficacy. The frequency of medication is kept to be used twice a day, and the application time is 4-6 hours each time. After the last application is completed, the next application is performed at least 1 hour apart.
为了使每次敷药的效果达到最佳,每次换药前,先使用20-30℃的温水清洗患处,将上一次涂覆的中药敷料完全清洗掉以后,再涂覆新的中药敷料。使用温水不仅可以轻松洗去已经干涸的中药敷料块,而且利用了热胀冷缩的原理,使患处皮肤毛孔张开,便于新药涂覆后快速吸收,确保药力充分显现。In order to achieve the best effect of each dressing, wash the affected area with warm water at 20-30°C before each dressing change, and then apply a new Chinese herbal dressing after completely washing off the last applied Chinese herbal dressing. Using warm water can not only easily wash away the dried traditional Chinese medicine dressing, but also utilizes the principle of heat expansion and contraction to open the skin pores of the affected area, which facilitates the rapid absorption of the new medicine after application, ensuring the full efficacy of the medicine.
按照上述方法,连续敷药3-5天即可见效,炎症减轻或局部症状缓解,肉眼可见症状明显改善。According to the above method, continuous application of the medicine for 3-5 days will result in effective results, the inflammation will be relieved or the local symptoms will be relieved, and the symptoms can be obviously improved by naked eyes.
下面通过临床实验来进行对比分析,以说明本发明的疗效。Carry out comparative analysis by clinical experiment below, to illustrate the curative effect of the present invention.
首先介绍静脉炎的诊断标准和用药效果判断标准,具体如下:Firstly, the diagnostic criteria of phlebitis and the criteria for judging the effect of medication are introduced, as follows:
(1)诊断依据与分级:(1) Diagnosis basis and classification:
根据INS《输液治疗实践标准》(2016年修订版)中静脉炎量表的分级诊断标准:According to the grading diagnostic criteria of the Phlebitis Scale in the INS "Practice Standards for Infusion Therapy" (2016 revision):
0级:没有症状;Grade 0: no symptoms;
1级:穿刺部位发红,伴有或不伴有疼痛;Grade 1: Redness at the puncture site, with or without pain;
2级:穿刺部位疼痛伴有发红和/或水肿;Grade 2: Pain at the puncture site with redness and/or edema;
3级:穿刺部位疼痛伴有发红,有条索状物形成,可触摸到条索状的静脉;Grade 3: Pain at the puncture site accompanied by redness, cord-like formation, and cord-like veins can be palpated;
4级:穿刺部位疼痛伴有发红疼痛,有条索状物形成,可触摸到条索状的静脉,其长度>1英寸(2.54厘米),有脓液流出。Grade 4: Puncture site pain with redness, cord formation, palpable cord-like veins > 1 inch (2.54 cm) in length, and pus discharge.
(2)用药效果判断标准:(2) Criteria for judging drug effect:
根据INS《输液治疗实践标准》(2016年修订版)中静脉炎量表的分级诊断标准进行评定中的0级-4级评定:According to the grading diagnostic criteria of the phlebitis scale in the INS "Infusion Therapy Practice Standards" (2016 revision), the 0-4 grades in the evaluation are evaluated:
治愈:用药后静脉炎分级为0级;Cure: the grade of phlebitis after medication is grade 0;
有效:用药后静脉炎分级下降2级;Effective: the grade of phlebitis decreased by 2 grades after medication;
部分有效:用药后静脉炎分级下降1级;Partially effective: the grade of phlebitis decreased by 1 grade after medication;
无效:症状无明显改变。总有效率=(治愈例数+有效例数+部分有效例数)/总例数*100%。Ineffective: no significant change in symptoms. Total effective rate=(number of cured cases+number of effective cases+number of partially effective cases)/total number of cases*100%.
除此之外,护理满意度调查,分为非常满意、满意、一般、不满意四个程度,总满意度=(非常满意例数+满意例数)/总例数*100%。In addition, the nursing satisfaction survey is divided into four levels: very satisfied, satisfied, average, and dissatisfied. Total satisfaction = (very satisfied cases + satisfied cases) / total cases * 100%.
本实施例开展了两类临床实验:针对上述3个实施例中的配方开展的临床实验,以及用3个配方中优选后的最佳配方与现有技术中的硫酸镁湿热敷法进行疗效对比实验,下面一一介绍。This embodiment carried out two types of clinical experiments: the clinical experiment carried out for the formulas in the above three embodiments, and the curative effect comparison of the best formula after optimization among the three formulas and the magnesium sulfate hot compress method in the prior art The experiments are introduced one by one below.
临床实验一:针对上述3个实施例的配方做临床实验。Clinical experiment 1: Conduct clinical experiments on the formulations of the above three embodiments.
征集120例静脉炎患者,分为1-3组,每组随机分配40例,分别使用前述实施例1-3中的中药配方制成的中药敷料,在使用相同用药方法的情况下,护理满意度相同,其疗效分别如下表1:Collect 120 cases of phlebitis patients, divide them into 1-3 groups, assign 40 cases randomly in each group, use the traditional Chinese medicine dressings made of the traditional Chinese medicine formula in the above-mentioned examples 1-3 respectively, under the situation of using the same medication method, the nursing is satisfactory The degrees are the same, and their curative effects are shown in the following table 1:
表1三组配方治疗效果统计表Table 1 Three groups of formula treatment effect statistical table
通过实验发现,3个配方均有无效情况,但以有效为主,其中实施例3以治愈和有效占比最大,在所有实施例中,疗效最佳,可作为最优配方进行后期的推广应用处方。Through experiments, it was found that all the three formulas were ineffective, but they were mainly effective. Among them, Example 3 had the largest proportion of cure and effectiveness. Among all the examples, the curative effect was the best, and it can be used as the optimal formula for later promotion and application. prescription.
临床实验二:用实施例3的配方、使用方法与现有技术中的硫酸镁湿热敷法进行对比实验。Clinical experiment 2: Comparative experiments were carried out with the formula and usage method of Example 3 and the magnesium sulfate wet heat compress method in the prior art.
为了更准确的判断疗效,本临床实验征集66例静脉炎患者,并对患者的详情进行明确,具体情况如下:In order to judge the curative effect more accurately, 66 patients with phlebitis were recruited in this clinical experiment, and the details of the patients were clarified. The details are as follows:
输液性静脉炎66例,其中男性25例,女性41例,年龄46~90岁,平均年龄(74±3.2岁)。静脉炎发生部位:手背9例,前臂36例,上臂6例,足踝8例,小腿7例。发生静脉炎前输入的液体种类:其中普通液体9例,胺碘酮12例,20%甘露醇6例,蔗糖铁13例,多种微量元素8例,人血白蛋白1例,复方氨基酸6例,七叶皂苷钠6例,中成药5例,其中1例为拔针后静脉炎,其余均为输液过程中发生的静脉炎。将以上病例按发生静脉炎的先后顺序分组,单号为观察组,双号为对照组,每组各33例患者,其中观察组男11例,女22例,年龄47岁~90岁,平均年龄(73.7±3.2岁),对照组男14例,女19例,年龄46岁~90岁,平均年龄(73.2±3.2岁)。两组患者的年龄、静脉炎发生部位、输入液体等基线资料比较差异无统计学意义(P>0.05),具有可比性。There were 66 cases of infusion phlebitis, including 25 males and 41 females, aged 46 to 90 years, with an average age (74±3.2 years). Phlebitis occurred in 9 cases on the back of the hand, 36 cases in the forearm, 6 cases in the upper arm, 8 cases in the ankle, and 7 cases in the calf. Types of liquids infused before the occurrence of phlebitis: 9 cases of ordinary liquid, 12 cases of amiodarone, 6 cases of 20% mannitol, 13 cases of iron sucrose, 8 cases of various trace elements, 1 case of human serum albumin, and 6 cases of compound amino acids For example, 6 cases of sodium aescinate and 5 cases of Chinese patent medicine, one of which was phlebitis after needle withdrawal, and the rest were phlebitis that occurred during infusion. The above cases were grouped according to the sequence of occurrence of phlebitis. The odd number was the observation group, and the even number was the control group. There were 33 patients in each group, including 11 males and 22 females in the observation group, aged 47 to 90 years old. Age (73.7±3.2 years), the control group had 14 males and 19 females, ranging from 46 to 90 years old, with an average age of (73.2±3.2 years). There was no significant difference in baseline data such as age, phlebitis site, and infusion fluid between the two groups (P>0.05), which were comparable.
以上病例中,分级为4级静脉炎的有24例,3级静脉炎的有23例,2级静脉炎的有19例,同时,所有病例均排除糖尿病、外周血管病变、穿刺部位皮肤病变和血液动力学改变。两组病例静脉炎分级差异比较无统计学意义(P>0.05),具有可比性。Among the above cases, there were 24 cases of grade 4 phlebitis, 23 cases of grade 3 phlebitis, and 19 cases of grade 2 phlebitis. At the same time, all cases were excluded from diabetes, peripheral vascular disease, puncture site skin lesions and Hemodynamic changes. There was no significant difference in the grading of phlebitis between the two groups (P>0.05), and they were comparable.
药品使用方法:How to use the drug:
患者在输液时,一经发生静脉炎,即拔除留置针导管,停止在此肢体上输液,并抬高患肢。During infusion, once phlebitis occurs, the indwelling needle catheter should be pulled out, the infusion on this limb should be stopped, and the affected limb should be raised.
观察组患者给予如下处理:使用本发明提供的中药敷料,将干糊状敷料均匀涂抹于患处,厚度约硬币厚度。然后用创可贴粘贴在中药敷料表面,将中药敷料遮盖并固定。等待药物涂抹在患处持续5个小时后,撕掉创可贴,待中药敷料自然脱落。撕掉创可贴2个小时后,先使用20-30℃的温水清洗患处,将残留在患处的药渣清洗掉,使患处保持干净状态,再按照上一次上药方式涂抹中药敷料,持续敷药5个小时,撕掉创可贴,2个小时后用温水清洗患处。按照此法,每天用药两次,连续用药5天。白天用药。Observation group patient is given following treatment: use Chinese medicine dressing provided by the present invention, dry pasty dressing is evenly applied to affected part, thickness is about the thickness of a coin. Then paste it on the surface of the traditional Chinese medicine dressing with a band-aid, and cover and fix the traditional Chinese medicine dressing. Wait for the medicine to smear on the affected area for 5 hours, then tear off the band-aid, and wait for the traditional Chinese medicine dressing to fall off naturally. After tearing off the band-aid for 2 hours, first wash the affected area with warm water at 20-30°C, and wash off the residue left on the affected area to keep the affected area clean. After 2 hours, tear off the band-aid, and wash the affected area with warm water after 2 hours. According to this method, the drug was administered twice a day for 5 consecutive days. Take medication during the day.
对照组患者给予如下处理:按照公知的硫酸镁湿热敷法,用温度40~50℃的50%硫酸镁湿纱布敷于患处,每40分钟更换一次纱布,每天更换5~6次,连续用药5天,白天用药。The patients in the control group were treated as follows: according to the known magnesium sulfate wet heat compress method, apply 50% magnesium sulfate wet gauze at a temperature of 40-50°C to the affected area, change the gauze every 40 minutes, and change it 5-6 times a day. Day, medication during the day.
本临床实验采用SPSS21.0进行统计分析,计数资料采用x±s进行统计描述,计量资料采用n和百分比进行统计描述,两组间的治疗有效率和满意率比较采用卡方检验,以P<0.05为差异有统计学意义。治疗效果如表2所示,护理满意度如表3所示。In this clinical experiment, SPSS21.0 was used for statistical analysis. The count data was statistically described by x±s, and the measurement data was statistically described by n and percentage. 0.05 was considered statistically significant. The treatment effect is shown in Table 2, and the nursing satisfaction is shown in Table 3.
表2观察组和对照组治疗效果统计表Table 2 Statistical Table of Treatment Effects of Observation Group and Control Group
表3观察组和对照组护理满意度统计表Table 3 Statistical Table of Nursing Satisfaction of Observation Group and Control Group
由表2可以看出,观察组的治愈和有效人数高于对照组,且无效人数远低于对照组,由此可见,本发明提供的中药敷料及使用方法对输液性静脉炎的疗效十分明显,且明显优于硫酸镁湿热敷法。由表3可以看出,观察组的护理满意度中“非常满意”远高于对照组,且不满意人数远少与对照组,由此可见,本发明提供的中药敷料及使用方法在进行治疗时,对患者的护理整体满意度远高于使用硫酸镁湿热敷法。As can be seen from Table 2, the cured and effective number of observation group is higher than matched group, and the invalid number is far lower than matched group, thus it can be seen that the curative effect of traditional Chinese medicine dressing and using method provided by the invention is very obvious to infusion phlebitis , and significantly better than magnesium sulfate hot compress method. As can be seen from Table 3, "very satisfied" in the nursing satisfaction of the observation group is much higher than that of the matched group, and the number of unsatisfied people is far less than that of the matched group. It can be seen that the traditional Chinese medicine dressing provided by the present invention and the use method are being treated. Overall satisfaction with patient care was much higher than with magnesium sulfate moist heat compresses.
综上所述,采用本发明提供的中药敷料及使用方法来治疗静脉炎,效果显著,治愈率高,且使用方便,护理简单,与现有技术相比,具有突出的实质性特点和显著的进步。In summary, adopting the traditional Chinese medicine dressing provided by the present invention and its method of use to treat phlebitis has remarkable effect, high cure rate, convenient use, and simple nursing. Compared with the prior art, it has outstanding substantive features and remarkable advantages progress.
为了便于将本发明中的中药敷料形成产业化,实现大规模推广销售和使用,本发明还提供了一种由上述中药敷料制成的粘贴式膏药,其整体结构类似于现有的创可贴,包括膏药基体层、膏药保护层,和夹在膏药基体层、膏药保护层之间的中药敷料,其中,中药敷料设置于膏药基体层的中部,在该膏药基体层的两端分别设置有粘贴层,膏药保护层通过与膏药基体层两端的粘贴层粘连,将中药敷料包覆在膏药基体层与膏药保护层之间。使用时,只需要将膏药保护层撕掉,然后将中药敷料对准患处,通过粘贴层粘贴在患者皮肤上,即可完成敷药。该粘贴式膏药不仅携带方便,使用无技术要求,患者自己即可使用,而且便于长期存放,非常适合广泛推广,具有很高的实用价值。In order to facilitate the industrialization of the traditional Chinese medicine dressing in the present invention and realize large-scale promotion, sales and use, the present invention also provides a sticky plaster made from the above-mentioned traditional Chinese medicine dressing, whose overall structure is similar to the existing band-aid, including A plaster base layer, a plaster protective layer, and a traditional Chinese medicine dressing sandwiched between the plaster base layer and the plaster protective layer, wherein the traditional Chinese medicine dressing is arranged in the middle of the plaster base layer, and adhesive layers are respectively arranged at both ends of the plaster base layer, The plaster protective layer is adhered to the adhesive layer at both ends of the plaster base layer, and the traditional Chinese medicine dressing is wrapped between the plaster base layer and the plaster protective layer. When in use, you only need to tear off the protective layer of the plaster, then align the traditional Chinese medicine dressing on the affected area, and stick it on the patient's skin through the adhesive layer to complete the dressing. The adhesive plaster is not only convenient to carry, has no technical requirements for use, can be used by patients themselves, and is convenient for long-term storage, is very suitable for wide promotion and has high practical value.
上述实施例仅为本发明的优选实施方式之一,不应当用于限制本发明的保护范围,但凡在本发明的主体设计思想和精神上作出的毫无实质意义的改动或润色,其所解决的技术问题仍然与本发明一致的,均应当包含在本发明的保护范围之内。The above-mentioned embodiment is only one of the preferred implementation modes of the present invention, and should not be used to limit the scope of protection of the present invention, but any modification or embellishment without substantive significance made on the main design concept and spirit of the present invention shall be solved by it. If the technical problems are still consistent with the present invention, all should be included in the protection scope of the present invention.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211048189.2A CN115252746A (en) | 2022-08-30 | 2022-08-30 | Traditional Chinese medicine for treating phlebitis, traditional Chinese medicine dressing prepared from traditional Chinese medicine and adhesive plaster |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211048189.2A CN115252746A (en) | 2022-08-30 | 2022-08-30 | Traditional Chinese medicine for treating phlebitis, traditional Chinese medicine dressing prepared from traditional Chinese medicine and adhesive plaster |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115252746A true CN115252746A (en) | 2022-11-01 |
Family
ID=83755171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211048189.2A Pending CN115252746A (en) | 2022-08-30 | 2022-08-30 | Traditional Chinese medicine for treating phlebitis, traditional Chinese medicine dressing prepared from traditional Chinese medicine and adhesive plaster |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115252746A (en) |
-
2022
- 2022-08-30 CN CN202211048189.2A patent/CN115252746A/en active Pending
Non-Patent Citations (4)
Title |
---|
傅建珍等: "五种不同调配如意金黄散治疗静脉炎的护理效果比较", 中国实用医药, vol. 10, no. 21, pages 217 - 218 * |
吴曦: "如意金黄散临证验案举隅", 河南中医, vol. 33, no. 7, pages 1159 - 1160 * |
张肖红等: "如意金黄散治疗胺碘酮所致静脉炎的疗效观察", 世界最新医学信息文摘, vol. 15, no. 15, pages 165 * |
陈美华等: "如意金黄散防治静脉炎研究进展", 中国乡村医药杂志, pages 76 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3466447B1 (en) | Pharmaceutical composition for treating multiple forms of skin wounds and manufacturing method thereof | |
CN101214286B (en) | Chinese medicine white spirit preparations for effectively treating rheumatic pain diseases | |
CN102091203A (en) | External traditional Chinese medicine preparation for treating chronic wounds and preparation method thereof | |
CN101406557A (en) | External-use Chinese medicine for treating burn, scald and various skin injuries | |
CN103446261A (en) | Chinese medicinal composition used for preventing and/or treating related skin lesion in tumour treatment | |
CN104547188B (en) | One kind treats cirsoid external preparation and preparation method thereof | |
CN114159511B (en) | Traditional Chinese medicine preparation for preventing and treating radioactive skin injury and preparation method thereof | |
CN101062065B (en) | Sore carbuncle plaster | |
CN106963923A (en) | A kind of Chinese medicine composition and preparation method and application with analgesic activity | |
CN115252746A (en) | Traditional Chinese medicine for treating phlebitis, traditional Chinese medicine dressing prepared from traditional Chinese medicine and adhesive plaster | |
CN1326546C (en) | Pure Chinese medicinal preparation for external treating burn and scald | |
CN111821373B (en) | Traditional Chinese medicine hydrogel external application patch for treating phlebitis | |
CN104524218A (en) | Preparation method for nursing infilling for cervical laceration | |
CN104706749B (en) | A kind of Chinese medicine composition for treating lumbar vertebrae shoulder disc protrusion | |
CN102357215A (en) | Ointment for treating right hypochondriac distention and pain caused by acute and chronic cholecystitis | |
CN101011511A (en) | Externally applied medicament for treating soft tissue injury | |
CN111658716A (en) | Hydrogel magnetic therapy traditional Chinese medicine plaster and preparation method thereof | |
CN105168625B (en) | A kind of clinical care is used for the treatment of the Chinese medicine liniment of two, three phase decubital ulcers | |
CN1883565A (en) | Gel for treating rheumatic arthritis and traumatic injury and method for preparing same | |
CN110302228A (en) | A kind of biological agent that treating hemorrhoid and its application | |
CN104958613B (en) | Chinese medicine composition of malicious decomposed type decubital ulcer and preparation method thereof is accumulate in a kind for the treatment of | |
CN114246926B (en) | A kind of external Chinese medicine composition for treating skin warts and its preparation method and application | |
CN1170570C (en) | Detoxicating ointment for treating burn and scald and its preparing process | |
CN101607069B (en) | Chinese traditional medicine for treating phlebitis, old lower extremity venous ulcer and venous purpura disease | |
CN101554432B (en) | Fumigating and washing medicine for curing hemorrhoids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20221101 |
|
RJ01 | Rejection of invention patent application after publication |